News

Lilly announces osteoporosis drug study results

BY Alaric DeArment

INDIANAPOLIS — A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.

Lilly released results of a phase-3 study of Forteo (teriparatide [rDNA origin]) in postmenopausal women with osteoporotic vertebral fractures that compared the drug with risedronate, originally marketed by Warner Chilcott under the brand name Actonel. The study found no difference between Forteo and risedronate in the ability to reduce the worst back pain by 30% after six months, but patients using Forteo showed greater increases in bone mineral density and fewer new vertebral fractures. Results of the study are in the August issue of the journal Osteoporosis International.

"With many available options to treat osteoporosis, this study is important because it compares two established osteoporosis medicines in a direct, head-to-head design," said Peyman Hadji, Philipps-University of Marburg endocrinology, osteoporosis and reproductive medicine department head and lead study investigator.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Bad economy doesn’t stop high BTS spending, survey finds

BY Alaric DeArment

AUSTIN, Texas — Nearly 80% of parents are spending up to $500 for back-to-school shopping, according to a survey by an online coupon site.

RetailMeNot.com announced Tuesday results of a survey that also found more than half of parents prefer to get a head-start on BTS shopping in July and August, rather than waiting until after the school year begins. The study, conducted with Ipsos Public Affairs, surveyed 1,041 adults online who had a child younger than 18 years old from Ipsos and had a 3% margin of error.

"Contributing to the stress, a significant majority of parents are spending hundred of dollars per child on back-to-school purchases in a still-sluggish economy," RetailMeNot Insider senior editor Trae Bodge said. "Parents should take this opportunity to involve their kids in planning and budgeting for back-to-school expenses to teach the difference between wants versus needs."

The survey also found that 83% of the parents spending up to $500 per child use coupons when they shop. Meanwhile, 22% start their BTS shopping in July, but 32% wait until August. Most of parents’ back-to-school budgets are for clothing, which 35% of respondents said would account for most of their spending, while 34% said school supplies would account for at least 30% of spending. More than a quarter said they found BTS shopping routine, including 31% of fathers, and 21% said they found it fun, while 29% found it annoying or stressful; 27% of mothers said they found BTS shopping fun, compared with 13% of fathers, and 15% of fathers found it annoying, compared with 8% of mothers.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Nordic Naturals launches Nordic Omega-3 Jellies for kids

BY Allison Cerra

WATSONVILLE, Calif. — Nordic Naturals has introduced a new kid-friendly line of supplements.

Nordic Omega-3 Jellies are fish-shaped jellies made from purified fish oil, sustainably sourced from anchovies and sardines, and then specially formulated for children ages 2 years and older. Each chewable touts 250 mg of docosahexaenoic acid and eicosapentaenoic acid. Each box contains 36 individual packs.

"When formulating this product, we focused on a chewable omega-3 that delivered on dosage and taste, plus convenient packaging that would delight parents," Nordic Naturals chief medical officer Keri Marshall said. "Children want a fun product that tastes great, while parents want concentration and convenience. This product is a win-win."

Nordic Naturals products are sold at stores nationwide.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES